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Ischemic heart diseaseAbstract Objective: The purpose of our study was to assess the incidence and predictors of contrast
induced nephropathy (CIN) in unselected patients undergoing coronary intervention either coronary
angiography (CA) or percutaneous coronary interventions (PCI), at Assiut university hospitals.
Background: CIN is a frequent, potentially lethal complication after coronary intervention. It is the
3rd most common cause of hospital-acquired acute renal failure.
Patients and methods: This is an observational prospective cohort study. Two hundred consecutive
patients betweenDecember 2011 and August 2012 underwent CA and PCI were enrolled in the study.
Blood samples were collected at baseline and 3 days after interventions. All patients were followed up
for 2 weeks for major adverse events.
Results: CIN was observed in 23 (11.5%) patients. According to Mehran risk score, 84.5% of our
patients had low risk for CIN, 15.5% had moderate risk for CIN, and no one had high risk score.
Multivariate logistic regression analysis of predictors for CIN, showed that the use of high osmolar
contrast media (CM) (Telebrix) was associated with 4 times higher incidence of CIN than the use of
low osmolar CM (Ultravest) (OR = 4.07; 95% CI = 1.1–15.1). None of our patients had clinical
signs or symptoms of acute renal failure, or required haemodialysis at 2 weeks of follow up.
Conclusion: Although most of our study population was at low risk, the incidence of CIN was
relatively high due to the use of high osmolar CM. Further studies are needed for cost effectiveness
in light of negligible clinical impact.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Cardiology.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).1. Introduction
Contrast induced nephropathy (CIN) represents a signiﬁcant
adverse event of contrast media (CM) administration, leading
to acute kidney impairment and, subsequently, to increased
hospital morbidity and mortality. 1 In the general population,
the incidence of CIN has been reported to be <2%, but it can
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and patients with diabetes mellitus (DM), chronic kidney dis-
ease (CKD), or congestive heart failure (CHF).2
Reduction in renal perfusion and toxic effects on the tubu-
lar cells caused by the direct and indirect effects of CM on the
kidneys are generally recognized as important mechanisms for
the development of CIN. Furthermore, contrast exposure
causes a certain degree of imbalance between increased renal
vasoconstriction and decreased vasodilatation; this leads to a
decrease in renal blood ﬂow and contraction of the afferent
glomerular arteriole, as well as renal ischemia and cell necro-
sis.3 Oxygen radicals released by the ischemia–reperfusion con-
tribute to not only renal damage but also the apoptosis of the
renal tubular epithelial cells.
In the majority of studies, the term CIN is widely deﬁned as
an absolute rise in the serum creatinine (SCr) level by at least
0.5 mg/dL (44 mmol/L) or an increase in SCr level of >25%
over baseline within 3 days following intravascular CM expo-
sure.4 The clinical presentation varies from asymptomatic to
symptomatic renal failure and death. Thus, it is important to
identify risk factors prior to the administration of a contrast
agent.
Many individual risk factors have been reported for the
development of CIN. Although the combination of two or more
risk factors is rather common in daily practice, the cumulative
risk of several variables on renal function was still unknown.5–7
This showed the need for global assessment of the impact of
these variables on the development of CINby using a simple risk
scoring system that can be easily conducted clinically.8
The purpose of our study was to assess the incidence and
predictors of CIN in unselected patients undergoing coronary
intervention either coronary angiography (CA) or percuta-
neous coronary interventions (PCI), at Assiut university
hospitals (AUH).
2. Methods
2.1. Study design and setting
We conducted a prospective cohort study at the catheteriza-
tion laboratory of AUH between December 2011 and
August 2012. The study protocol was reviewed and approved
by the institutional review committee, and all patients granted
their informed consent to be included in the study.
2.2. Study population
Two hundred consecutive unselected patients scheduled to
undergo a coronary procedure either CA or PCI were enrolled
in the study. Patients were excluded from the study if they had
end stage renal disease and on regular dialysis and those with
other contrast exposure within one week or less from the index
procedure.
The CM used was left to the discretion of the interventional
cardiologist. Main CM used in our laboratory is Telebrix
[produced by Guerbet Asia Paciﬁc and composed of
Meglumine; it is a High-Osmolar, Ionic CM (HOCM)].
Ultravist [produced by Bayer Healthcare and composed of
iopromide; it is a Low Osmolar, Non-Ionic CM (LOCM)] is
another option used only in selected high risk patients mainly
due to ﬁnancial constrain.2.3. Data collection and measurements
The demographic and clinical data were prospectively collect-
ed by our research team using a standardized ‘‘peri-procedural
datasheet’’. The patients were interviewed on the day of the
procedure and 2 weeks after.
2.3.1. Baseline characteristics
Demographic data (age, sex, length, and weight), risk factors,
previous treatment and type and indication for intervention
were collected. Body mass index (BMI) was calculated based
on height and weight (kg/m2).
2.3.2. Cardiac catheterization
CA and PCI were performed in accordance with established
clinical practice using standard diagnostic and guide catheters,
wires, balloon catheters, and stents via the femoral approach.
The amount of contrast media administered was decided by
the interventional cardiologist. Patients were treated in accor-
dance with the guidelines of the American College of
Cardiology/American Heart Association.9
2.3.3. Risk factors
All patients were admitted to the hospital one day before car-
diac catheterization. Risk stratiﬁcation for development of
CIN was calculated for all patients using the Mehran risk
score.7 That risk score includes hypotension (5 points, if sys-
tolic blood pressure <80 mm Hg for at least 1 h requiring
inotropic support), use of intra-aortic balloon pump (5 points),
congestive heart failure (5 points, if class III/IV by New York
Heart Association classiﬁcation or history of pulmonary ede-
ma), age (4 points, if >75 years), anemia (3 points, if hemato-
crit <39% for men and <36% for women), diabetes mellitus
(3 points), contrast media volume (1 point per 100 mL), esti-
mated glomerular ﬁltration rate (GFR; GFR in mL/min per
1.73 m2; 2 points, if GFR 60–40; 4 points, if GFR 40–20; 6
points, if GFR< 20). A risk score of <6, 6–10, 11–16, and
>16 indicates a risk for CIN of 7.5%, 14%, 26%, and 57%,
respectively 7.
2.3.4. CIN prophylaxis
We also used the ‘‘peri-procedural datasheet’’ to assess
whether or not patients were instructed to increase oral ﬂuid
intake, discontinue potential nephrotoxic medication/met-
formin or received prophylactic intravenous hydration in
accordance with the hospital CIN prevention protocol. That
protocol indicates that patients who need prophylactic intra-
venous hydration should receive 0.9% sodium chloride
(NaCl), 3–4 ml/kg/h for four hours before and after interven-
tion. In patients with severe kidney disease or congestive heart
failure administration of 1 ml/kg/h for 12 h is recommended
before and after intervention. The ﬁnal decision to actually
apply prevention measures using intravenous hydration in
patients at risk was left to the discretion of the treating
physician.
2.3.5. Kidney function
Serum creatinine concentrations and eGFR were determined
at hospital admission (prior to the procedure), and on days
1, 2, and 3 after the procedure. The changes of serum
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according to the Modiﬁcation of Diet in Renal Disease
(MDRD) formula.10,11 CIN was deﬁned as an increase in the
serum creatinine level of more than 0.5 mg/dl or more than
25% from baseline within 3 days after procedure without
any other identiﬁable cause of acute kidney injury.
2.3.6. Follow up
All patients were scheduled to undergo a clinical assessment
for the development of major adverse events (death and need
for hemodialysis), 2 weeks after the procedure. All patients
with CIN had another blood sample after 2 weeks for the
assessment of serum creatinine concentrations and eGFR.
2.4. Statistical analysis
Categorical data were presented as counts and proportions
(percentages) and compared by Pearson chi-square analysis or
Fischer’s exact test if the expected cell count for a 2 · 2 table
was <5. Normal distribution of continuous data was tested
using a Kolmogorov–Smirnov test. Continuous and normally
distributed data are presented as mean ± 1 standard deviation
and were compared by two-tailed unpaired t-test. Univariate
and Multivariate logistic regression analyses were performed
using the stepwise method (SLE = 0.1, SLS = 0.05; SLE: the
signiﬁcance level for entering effects, SLS: the signiﬁcance level
for removing effects) to evaluate potential risk factors for CIN.
Variables included in the multivariate logistic model were age
(cutoff value = 65 years old), diabetes, PCI procedure, anemia,
congestive heart failure, intra-aortic balloon pumping, preop-
erative hypotension, and SCr (cutoff valueP 1.5 mg/dL).
Signiﬁcant variables only were included in the multivariateTable 1 Baseline characteristics of patients with and without contr
Overall
(n= 200)
Age (years) 55.5 ± 8.8
AgeP 65 y, n (%) 30 (15%)
Sex: male 155 (78%)
BMI, median (IR) 27.5
(25.4–30.2)
Smoking habit (%) 71 (36%)
Hypertension, n (%) 101 (51%)
Previous MI, n (%) 122 (61%)
Dyslipidemia, n (%) 62 (31%)
History of CKD, n (%) 36 (18%)
Diabetes mellitus, n (%) 77 (39%)
Anemia, n (%) 3 (1.5%)
Hypotension, n (%) 0
IABP, n (%) 0
CHF, n (%) 0
Previous treatment
ACEI or ARB, n (%) 16 (8%)
Statins, n (%) 24 (12%)
Diuretic agents, n (%) 6 (3%)
Insulin therapy, n (%) 12 (6%)
Oral antidiabetic agents, n (%) 23 (11%)
ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin rec
kidney disease; CHF, congestive heart failure; IABP, intra-aortic ballo
percutaneous coronary intervention.logistic regression analysis. These comparisons were performed
using the SPSS version 16.0 software package (SPSS Inc.,
Chicago, IL), and a p value of 60.05 was considered to be
signiﬁcant.
3. Results
3.1. Patients characteristics
A total of 200 unselected patients were included in our study.
Among these patients 23 (11.5%) developed CIN. These
patients tend to be older, using ACEI, ARB and diuretic
agents more frequently compared with those who did not
develop CIN (Table 1). The incidence of diabetes and CKD
was not signiﬁcantly different between those who developed
CIN and those who did not. The overall contrast volumes used
were not signiﬁcantly different between those who developed
CIN (204 ± 141) and those who did not (150 ± 98,
p= 0.09), but the use of more than 400 mL of contrast was
signiﬁcantly higher in patients with CIN (17%) compared with
those without CIN (5%, P= 0.03; Table 2). The use of
HOCM (Telebrix) tends to be higher in patients with CIN
compared with those without (Table 2).
3.2. Kidney function (serum creatinine and estimated glomerular
ﬁltration rate)
Table 2 showed that, the baseline SCr was signiﬁcantly higher
(0.99 ± 0.36) compared with those without (0.80 ± 0.32,
p= 0.01); also the baseline eGFR was signiﬁcantly lower
(83.4 ± 16) in patients with CIN compared with those without
(105.6 ± 10, p= 0.01). Peak eGFR reduced signiﬁcantly inast induced nephropathy.
CIN No-CIN P
(n= 23) (n= 177)
57.9 ± 6. 3 55.1 ± 9. 1 0.07
3 (13%) 27 (15%) 0.56
20 (87%) 135 (77%) 0.41
27.8 27.3 0.89
(25.8–30.2) (25.5–30.1)
9 (38%) 62 (35%) 0.12
11 (46%) 90 (51%) 0.66
16 (70%) 106 (60%) 0.83
7 (30%) 55 (31%) 0.58
5 (22%) 31 (18%) 0.40
10 (44%) 67 (38%) 0.46
0 (0%) 3 (1.7%) 0.69
0 0 –
0 0 –
0 0 –
4 (17%) 12 (7%) 0.06
5 (19%) 19 (11%) 0.18
2 (8%) 4 (2%) 0.09
1 (4%) 11 (6%) 0.46
5 (19%) 18 (10%) 0.07
eptor blocker; CIN, contrast-induced nephropathy; CKD, chronic
on pump; IR, interquartile range; MI: Myocardial infarction; PCI,
Table 2 Procedural-related characteristics of patients with and without contrast induced nephropathy.
Characteristics Overall CIN No-CIN P
(n= 200) (n= 23) (n= 177)
Coronary angiography, n (%) 100 (50%) 10 (43.5%) 90 (50.8%) 0.39
PCI, n (%) 100 (50%) 13 (56.5%) 87 (49.2%) 0.56
Contrast volume (mL) 157 ± 105 204 ± 141 150 ± 98 0.09
Contrast volumeP 400 mL 12 (6%) 4 (17%) 8 (5%) 0.03
IOCM
HOCM (Telebrix), n (%) 145 (72.5%) 20 (87%) 125 (71%) 0.07
LOCM (Ultravest), n (%) 55 (27.5%) 3 (13%) 52 (29%)
Baseline SCr, (mg/dl) 0.90 ± 0.3 0.99 ± 0.36 0.80 ± 0.32 0.01
Baseline CrCl, mL/min 103.7 ± 14.8 94.3 ± 16.6 115.3 ± 12.8 0.01
Baseline eGFR (ml/min/1.73 m2) 92.9 ± 2.1 83.4 ± 6 105.6 ± 10 0.01
Peak SCr, (mg/dl) 1.0 ± 0.36 1.3 ± 0.55 0.97 ± 0.31 0.01
Peak eGFR (ml/min/1.73 m2) 82.3 ± 2.2 60.3 ± 9.8 85.4 ± 6.6 0.01
IV Hydration given, n (%) 50 (25%) 7 (30%) 43 (24%) 0.51
Mehran score (IR) 3.2 ± 2.3 3.9 ± 2.3 3.1 ± 2.3 0.12
(1–11) (1–9) (1–11)
CIN, contrast-induced nephropathy; SCr, serum creatinine; CrCl, creatinine clearance; eGFR, estimated glomerular ﬁltration rate; IABP, intra-
aortic balloon pump; IOCM, intraoperative contrast media; IV, intravenous; IR, interquartile range; HOCM, high osmolar contrast media;
LOCM, low osmolar contrast media; PCI, percutaneous coronary intervention.
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(85.4 ± 16 ml/min/1.73m2, p= 0.01). Table 3 showed highly
signiﬁcant difference in the peak increase in the serum creati-
nine concentration from baseline to day 3 between patients
with CIN compared to those without.
3.3. Predictors of CIN
All included patients were subjected to total risk calculation
and divided accordingly into low, moderate, high and very
high risk according to Mehran risk score. There were 169
(84.5%) patients at low risk, 31 (15.5%) patients at moderate
risk and none at high or very high risk according to Mehran
risk score system. In the low risk group 18 patients out of
169 developed CIN with an incidence of 11%. In the moderate
risk group 5 patients out of 31 patients developed CIN with an
incidence of 16% (p= 0.56) (Fig. 1).
The peri-procedural IV hydration was not signiﬁcantly
different between those who developed CIN and those who
did not (Table 2). Furthermore, the Mehran risk score was
not higher in patients with CIN (3.9 ± 2.3) than in those
without CIN (3.1 ± 2.3, p= 0.12).
Univariate and Multivariate logistic regression analyses
were performed to evaluate potential risk factors for CIN.
Variables included in the multivariate logistic model were age
(cutoff value = 65 years), diabetes, PCI procedure, anemia,
congestive heart failure, intra-aortic balloon pumping,Table 3 Peak increase in the serum creatinine concentration from
Group No. of patients Increase in
Mean ± SD
Milligrams
Overall 200 0.03 ± 0.31
CIN 23 0.49 ± 0.37
No-CIN 177 0.00 ± 0.2
CIN, contrast-induced nephropathy.
a p< 0.001 comparing peak increase difference between patients withpreoperative hypotension, and SCr (cutoff value P1.5 mg/dL).
Related factors such as intraaortic balloon pumping and
preoperative hypotension were not included in the multivariate
logistic model because none of the 200 patients received intra-
aortic balloon pumping or had preprocedural hypotension.
Univariate logistic regression analysis revealed that the use
of HOCM (Telebrix) and contrast volume more than 400 ml
were signiﬁcantly related to the incidence of CIN (Table 4).
Age was positively related to incidence of CIN. PCI procedure,
diabetes mellitus history and baseline SCr > 1.5 mg/dL were
not related to the incidence of CIN in our study population.
Furthermore, Mehran total risk score >6 did not show any
predictive value related to incidence of CIN (Table 4).
Signiﬁcant variables only were included in the multivariate
logistic regression analysis. The use of HOCM (Telebrix) and
contrast volume more than 400 ml were the only signiﬁcant
multivariable predictors of CIN. The incidence of CIN was 4
times higher in patients receiving HOCM (OR= 4.08, 95%
CI = 1.1–15.1).
3.4. Follow up
All patients were followed up for two weeks to assess incidence
of major adverse effects including death or need for hemodia-
lysis. None of our patients died or developed renal failure. All
patients with CIN had another blood sample and showed that
the SCr returned to baseline levels.baseline to day 3.
serum creatinine concentration
(95% CI) Median Range
per deciliter
0.00 0.00 to 1.4
a 0.41 0.2 to 1.4
4 0.00 0.00 to 0.6
CIN compared with those without CIN.
Figure 1 Incidence of contrast induced nephropathy in the study
group according to Mehran risk score system. The bars show the
numbers of patients with a contrast induced nephropathy (CIN)
and those without CIN in low andmoderate risk patients according
to Mehran risk score. There was no signiﬁcant difference in the
incidence of CIN between the 2 groups (p= 0.56).
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Main ﬁndings of our study were: (1) most of our unselected
study population was at low risk for development of CIN
(84.5%), (2) incidence of CIN was relatively high (11.5%),
(3) the use of HOCM (Telebrix) and higher contrast volume
were the only predictors of CIN in our study, (4) clinical
impact of CIN development was not relevant at 2 weeks of fol-
low-up.
4.1. CIN incidence
Among all procedures utilizing CM for diagnostic or therapeu-
tic purposes, CA and PCI are associated with the highest rates
of CIN.12 There was a high incidence of CIN in our study even
in patients with normal renal function and at low risk. In
accordance with Bouzas-Mosquera et al. 13 who reported
12% incidence of CIN however, his incidence was in a high
risk group undergoing primary PCI.
Although the risk of CIN after PCI in the general popula-
tion is low (0.6–3%, depending on the deﬁnition used),14 the
incidence can be considerably higher in risk subgroups.15–17Table 4 Univariate and multivariate analyses of predictors of cont
Predictors N (%) Univariate an
OR 9
Contrast type (Telebrix) 145 (72.5%) 3.77 1
Contrast volume (P400 mL) 12 (6%) 1.1 1
Age (P65 y) 30 (15%) 1.1 0
Sex (male) 155 (78%) 0.4 0
Total risk score (score > 6) 31 (16%) 1.2 0
DM 77 (39%) 0.8 0
SCr > 1.5 mg/dL 36 (18%) 0.9 0
Procedure (PCI) 100 (50%) 0.58 0
CIN, contrast-induced nephropathy; OR, odds ratio; CI, conﬁdence inter
failure; DM, diabetes mellitus; SCr, serum creatinine.Rihal et al. 18 reported that the incidence of CIN was 3.3%
in the interventional cardiology registry from Mayo Clinic
including 7586 patients. Nash et al. 12 stated that radiographic
CM are responsible for 11% of cases of hospital-acquired
renal insufﬁciency, the third most common cause of renal fail-
ure after impaired renal perfusion and the use of nephrotoxic
medications.
Mehran et al. 7 showed that the overall occurrence of CIN
in 8.357 patients was 13.1% (range 7.5–57.3% for a low
[<or = 5] and high [>or = 16] risk scores, respectively).
Gruberg et al., stated that CIN occurred in 1.2% of the
patients without risk factors, in 11.2% with one risk factor,
and in 42% of the patients with two or more risk factors.19
In our study the results showed that incidence was 11% in
the low risk group (total risk score 6 5) as compared with
16% in the moderate risk group (total risk score 6–10).
4.2. Predictors of CIN
Identifying patients at high risk of renal dysfunction after
cardiac catheterization is of utmost importance, given its prog-
nostic implications. Mehran et al. 7 assessed predictive factors
for CIN and developed a risk classiﬁcation in patients under-
going elective PCI. In our study, the volume of CM was similar
to that reported in previous studies.13 In accordance with our
study, Solomon et al. 20 reported that a higher volume of CM
is associated with a higher risk of CIN. Even relatively low
doses of CM (<100 mL) can result in permanent renal failure
and the need for dialysis in patients with CKD,21 and each
100-mL increment in contrast volume has been shown to result
in a 30% increase in the odds of CIN.22 An early study report-
ed that the limit of the dose of radiographic contrast in
patients with CKD (SCrP 1.8 mg/mL) can be calculated
using the following formula: 5 mL · body weight in kilograms
(maximum 300 mL) – SCR (mg/mL).23 Recent studies have
modiﬁed the method of renal function assessment and found
that the independent predictors of CIN are V/eGFRP 2.39
or V/CrClP 3.7 in different populations.23,24 These ﬁndings,
however, should be interpreted with care.25
In our study, the incidence of CIN was 4 times higher in
patients receiving HOCM compared to those using LOCM.
Types of contrast media (CM) were traditionally classiﬁed
according to their osmolality: high-osmolar CM (HOCM),
>1500 mOsm/kg (i.e., 5–8 times plasma); low-osmolar CM
(LOCM), 550–850 mOsm/kg (i.e., 2–3 times plasma); andrast-induced nephropathy.
alysis Multivariate analysis
5% CI P OR 95% CI P
.0–14.6 0.05 4.08 1.1–15.1 0.03
.00–1.01 0.05 1.01 1.00–1.01 0.01
.99–1.2 0.07 1.04 0.99–1.1 0.10
.1–1.6 0.2
.3–4.6 0.7
.2–2.2 0.6
.2–2.8 0.8
.2–1.6 0.3
val; PCI, percutaneous coronary intervention; CHF, congestive heart
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ma).26 However, products containing different concentrations
of iodine can change their osmolarity and viscosity properties,
which are important for the development of CIN.27
In accordance with our study, Barrett et al. 28 reported in a
metaanalysis of 45 trials that LOCMhave a lower risk of CIN in
both patients with existing renal failure (OR = 0.5, CI = 0.36–
0.68) and in those without prior renal failure (OR = 0.75,
CI = 0.52–1.1) compared with HOCM. Furthermore, the risk
of CIN is not homogeneous for all LOCM. In these meta-
analyses29,30 with two LOCM (iohexol and ioxaglate), the
authors found that the risk of CIN was higher than other
LOCM (e.g., iopamidol, iopromide, ioversol). Although the
lower osmolality of IOCM may decrease the incident adverse
effects, the higher viscosity of IOCM may block this protective
beneﬁt in comparison with LOCM. To date, no consensus has
been reached on the relative importance of osmolality and vis-
cosity.31 The current ACC/AHA guidelines recommend the
use of either IOCM or LOCM other than iohexol and ioxaglate
in patients with CKD undergoing angiography.32
In our locality ﬁnancial strain is a major issue determining
the treatment and preventive modalities. The cost of LOCM
(Ultravest) is twice the price of HOCM (Telebrix). This double
rise in price of CM seems to have no major clinical burden in
our study population in agreement with Moos et al.,33,34 who
reported that the clinical impact of CIN in one thousand
patients undergoing intravenous contrast enhanced computed
tomography is low. On the other hand, most of coronary inter-
vention studies reported higher incidence of major adverse
events in patients with CIN.5–7,9,10,32,35
4.3. Prognosis of CIN patients
All patients who were included in the study were followed after
2 weeks to assess major adverse effects as death or progressive
renal failure requiring dialysis, and the results revealed that the
kidney function of all of them recovered, serum creatinine
returned to the baseline and neither of them had developed
any of the major adverse effects (death or renal dialysis) in
agreement with Moos et al. 33,34, who reported that the clinical
impact of CIN in one thousand patients undergoing
intravenous contrast enhanced computed tomography is low.
On the other hand, Bouzas-Mosquera et al. 13 reported 14%
mortality in CIN patients after primary PCI, and Marenzi
et al. 36 reported a hospital mortality of 31% in those patients.
However, our study population was mainly a low risk group
compared to patients with STEMI undergoing primary PCI
in these studies who cannot receive pre-hydration protocols.
In our study, pre-hydration protocol used may explain the
absence of clinical events.
This study had several limitations; the small sample size
may have limited the power of our study to detect a signiﬁcant
association between CIN and the Mehran risk score analysis.
The number of patients is small (60 patients) for multivariate
analysis. Also the short duration of follow up may preclude
the detection of major adverse events.5. Conclusion
Although most of our study population was at low risk, the
incidence of CIN was relatively high due to the use of highionic CM. Further studies are needed for cost effectiveness in
light of negligible clinical impact.
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